Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 12;41(9):1296–1306. doi: 10.1038/s41587-022-01626-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a, Cytotoxicity of the anti-CD123 antibody (CD123-IgG1⁺) against AML blasts from patients. Malignant cells from seven patients with AML were used as targets and purified NK cells from ten healthy donors were used as effectors. Results are shown for all healthy donor NK cells tested. b, Phenotype of the malignant AML cells from patients used in a showing the expression of CD33, CD123, CD32a/b and CD64. FI, fluorescence intensity. c, Upper panels show the cytotoxicity of anti-CD123 antibody (CD123⁻IgG1⁺) against AML cell lines with and without expression of CD32 and CD64. MOLM-13 (CD32^lowCD64⁻) and THP-1 (CD32⁺CD64⁺) cells and THP-1 subclones with inactivated CD32 (CD32-KO CD64⁺) or CD64 (CD32⁺ CD64-KO) expression were used as the target cells, with purified resting NK cells from healthy donors as effectors (n = 3). Data of a and c are presented as mean values ± s.d. Lower panels show the phenotype of the AML cell lines expressing CD123, CD32 and CD64. Ab, antibody.